175 related articles for article (PubMed ID: 18165765)
21. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes.
Thai NL; Khan A; Tom K; Blisard D; Basu A; Tan HP; Marcos A; Fung JJ; Starzl TE; Shapiro R
Transplantation; 2006 Dec; 82(12):1621-4. PubMed ID: 17198247
[TBL] [Abstract][Full Text] [Related]
22. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years.
Stratta RJ; Alloway RR; Lo A; Hodge EE
Transplant Proc; 2005 Oct; 37(8):3531-4. PubMed ID: 16298651
[TBL] [Abstract][Full Text] [Related]
23. Pancreas transplantation at the University of Wisconsin.
Odorico JS; Leverson GE; Becker YT; Pirsch JD; Knechtle SJ; D'Alessandro AM; Sollinger HW
Clin Transpl; 1999; ():199-210. PubMed ID: 11038638
[TBL] [Abstract][Full Text] [Related]
24. Rejection after simultaneous pancreas-kidney transplantation.
Arbogast H; Malaise J; Illner WD; Tarabichi A; Dieterle C; Landgraf R; Land W;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii11-7, ii62. PubMed ID: 15814544
[TBL] [Abstract][Full Text] [Related]
25. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
[TBL] [Abstract][Full Text] [Related]
26. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
Baez Y; Giron F; Niño-Murcia A; Rodríguez J; Salcedo S
Transplant Proc; 2008 Apr; 40(3):697-9. PubMed ID: 18454990
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis.
Shou ZF; Zhou Q; Cai JR; Cheng J; He Q; Wu JY; Chen JH
Chin Med J (Engl); 2009 Jul; 122(14):1692-8. PubMed ID: 19719973
[TBL] [Abstract][Full Text] [Related]
28. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.
Muthusamy AS; Vaidya AC; Sinha S; Roy D; Elker DE; Friend PJ
Am J Transplant; 2008 Oct; 8(10):2126-31. PubMed ID: 18828772
[TBL] [Abstract][Full Text] [Related]
29. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Watson CJ; Bradley JA; Friend PJ; Firth J; Taylor CJ; Bradley JR; Smith KG; Thiru S; Jamieson NV; Hale G; Waldmann H; Calne R
Am J Transplant; 2005 Jun; 5(6):1347-53. PubMed ID: 15888040
[TBL] [Abstract][Full Text] [Related]
30. Fungal infections in transplant recipients receiving alemtuzumab.
Nath DS; Kandaswamy R; Gruessner R; Sutherland DE; Dunn DL; Humar A
Transplant Proc; 2005 Mar; 37(2):934-6. PubMed ID: 15848579
[TBL] [Abstract][Full Text] [Related]
31. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).
Gallon L; Gagliardini E; Benigni A; Kaufman D; Waheed A; Noris M; Remuzzi G
Clin J Am Soc Nephrol; 2006 May; 1(3):539-45. PubMed ID: 17699257
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous pancreas-kidney transplantation nine years after liver transplantation--a case report.
Marschalek J; Györi GP; Silberhumer GR; Jomrich G; Kristo I; Steininger R; Mühlbacher F; Berlakovich GA
Transplant Proc; 2012 Dec; 44(10):3041-3. PubMed ID: 23195023
[TBL] [Abstract][Full Text] [Related]
33. Emerging role of Alemtuzumab in renal and renal-pancreas transplantation.
Sureshkumar KK; Hussain SM; Zimmer BW; Marcus RJ
Expert Opin Biol Ther; 2008 Oct; 8(10):1605-25. PubMed ID: 18774927
[TBL] [Abstract][Full Text] [Related]
34. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion.
Silveira FP; Marcos A; Kwak EJ; Husain S; Shapiro R; Thai N; McCurry KR; Abu-Elmagd K; Paterson DL
J Infect; 2006 Oct; 53(4):241-7. PubMed ID: 16403576
[TBL] [Abstract][Full Text] [Related]
35. Pancreas-kidney transplantation in Japan: impact of cyclosporine on the development of immunosuppressive therapy.
Sugitani A; Ishibashi M; Ito T; Nakajima K; Matsuno N; Kanazawa Y; Motoyama K; Yamamoto H; Inoue S; Ota M; Yoshida JI; Tanaka M
Transplant Proc; 2004 Mar; 36(2 Suppl):356S-361S. PubMed ID: 15041368
[TBL] [Abstract][Full Text] [Related]
36. C4d positivity is often associated with acute cellular rejection in renal transplant biopsies following Campath-1H (Alemtuzumab) induction.
Zhang PL; Malek SK; Blasick TM; Pennington JR; Masker KK; Lun M; Potdar S
Ann Clin Lab Sci; 2007; 37(2):121-6. PubMed ID: 17522366
[TBL] [Abstract][Full Text] [Related]
37. Development of BK nephropathy in recipients of simultaneous pancreas-kidney transplantation.
Ison MG; Parker M; Stosor V; Kaufman DB
Transplantation; 2009 Feb; 87(4):525-30. PubMed ID: 19307788
[TBL] [Abstract][Full Text] [Related]
38. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
[TBL] [Abstract][Full Text] [Related]
39. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols.
Steurer W; Malaise J; Mark W; Koenigsrainer A; Margreiter R;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii54-62. PubMed ID: 15814551
[TBL] [Abstract][Full Text] [Related]
40. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
Schulz T; Papapostolou G; Schenker P; Kapischke M
Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
